All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 86 points (0.5%) at 17,915 as of Tuesday, Nov. 3, 2015, 11:55 AM ET. The NYSE advances/declines ratio sits at 1,603 issues advancing vs. 1,362 declining with 155 unchanged.

The Drugs industry currently sits up 1.0% versus the S&P 500, which is up 0.2%. Top gainers within the industry include Mylan ( MYL), up 3.5%, Perrigo ( PRGO), up 1.7% and Novo Nordisk A/S ( NVO), up 0.9%. On the negative front, top decliners within the industry include AMAG Pharmaceuticals ( AMAG), down 19.8%, Incyte ( INCY), down 2.6%, GlaxoSmithKline ( GSK), down 1.6%, Biomarin Pharmaceutical ( BMRN), down 1.3% and AbbVie ( ABBV), down 1.1%.

TheStreet would like to highlight 3 stocks pushing the industry higher today:

3. Illumina ( ILMN) is one of the companies pushing the Drugs industry higher today. As of noon trading, Illumina is up $5.57 (3.7%) to $154.41 on average volume. Thus far, 827,517 shares of Illumina exchanged hands as compared to its average daily volume of 1.9 million shares. The stock has ranged in price between $146.82-$154.56 after having opened the day at $147.75 as compared to the previous trading day's close of $148.84.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Illumina, Inc. provides sequencing and array-based solutions for genetic analysis in North America, Europe, Latin America, the Asia-Pacific, the Middle East, and South Africa. Illumina has a market cap of $20.7 billion and is part of the health care sector. Shares are down 19.4% year-to-date as of the close of trading on Monday. Currently there are 10 analysts who rate Illumina a buy, no analysts rate it a sell, and 8 rate it a hold.

TheStreet Ratings rates Illumina as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and notable return on equity. However, as a counter to these strengths, we find that the stock has had a generally disappointing performance in the past year. Get the full Illumina Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

2. As of noon trading, Teva Pharmaceutical Industries ( TEVA) is up $1.18 (1.9%) to $62.00 on light volume. Thus far, 1.4 million shares of Teva Pharmaceutical Industries exchanged hands as compared to its average daily volume of 5.0 million shares. The stock has ranged in price between $60.75-$62.12 after having opened the day at $60.87 as compared to the previous trading day's close of $60.82.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic, specialty, and other pharmaceutical products worldwide. The company operates in two segments, Generic Medicines and Specialty Medicines. Teva Pharmaceutical Industries has a market cap of $50.4 billion and is part of the health care sector. Shares are up 5.8% year-to-date as of the close of trading on Monday. Currently there are 12 analysts who rate Teva Pharmaceutical Industries a buy, 1 analyst rates it a sell, and 5 rate it a hold.

TheStreet Ratings rates Teva Pharmaceutical Industries as a buy. The company's strengths can be seen in multiple areas, such as its reasonable valuation levels, good cash flow from operations, expanding profit margins, solid stock price performance and largely solid financial position with reasonable debt levels by most measures. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full Teva Pharmaceutical Industries Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

1. As of noon trading, Valeant Pharmaceuticals International ( VRX) is up $0.73 (0.7%) to $101.20 on heavy volume. Thus far, 7.9 million shares of Valeant Pharmaceuticals International exchanged hands as compared to its average daily volume of 8.1 million shares. The stock has ranged in price between $99.73-$104.80 after having opened the day at $103.04 as compared to the previous trading day's close of $100.47.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Valeant Pharmaceuticals International, Inc. develops, manufactures, and markets pharmaceuticals, over-the-counter products, and medical devices worldwide. Valeant Pharmaceuticals International has a market cap of $32.2 billion and is part of the health care sector. Shares are down 29.8% year-to-date as of the close of trading on Monday. Currently there are 9 analysts who rate Valeant Pharmaceuticals International a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates Valeant Pharmaceuticals International as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, good cash flow from operations and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including a generally disappointing performance in the stock itself, unimpressive growth in net income and generally higher debt management risk. Get the full Valeant Pharmaceuticals International Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).